2008 In Review: China’s Major Legal & Regulatory Changes For Healthcare Sector
This article was originally published in PharmAsia News
Executive Summary
BEIJING - In a review of the major legal and regulatory measures that changed China's healthcare landscape in 2008, Chinese and European lawyers stated the merger of the State FDA into the Ministry of Health is likely to have the most significant impact into the future
You may also be interested in...
China’s 2009 Regulatory Changes Affect Drug, API And Device Makers
Tagging drugs, including imports, for electronic tracking starts in 2009, as do voluntary post-market studies that could portend a mandate.
China’s 2009 Regulatory Changes Affect Drug, API And Device Makers
Tagging drugs, including imports, for electronic tracking starts in 2009, as do voluntary post-market studies that could portend a mandate.
China’s 2009 Regulatory Changes Will Affect Makers of Drugs, APIs and Devices
BEIJING - An array of regulatory and legal changes covering pharmaceuticals and medical devices in China is likely to be launched or broadened this year, including new GMP guidelines, as the country aims to upgrade supervision of the entire health care sector, according to a leading Chinese lawyer in the area of life sciences-related issues and legislation